RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines ...Middle East

GAITHERSBURG, Md., March 29, 2022 /PRNewswire/ -- RNAimmune, Inc. (the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximately US$27 million Series A...

Hence then, the article about rnaimmune secures 27 million series a round of financing for development of mrna therapeutics and vaccines was published today ( Wednesday 30/03/2022 - 03:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines )

Also on site :

• Saudi Arabia to unify LPG gas cylinder prices nationwide from January 2026
• Two dozen killed in Ukrainian strike on Russian New Year’s celebration – governor
• Volunteer in Iran’s Revolutionary Guard reportedly killed during widening protests